Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2020-03-30 07:00:16
Bergen, Norway, March 30, 2020 - BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces today that Richard Godfrey, Chief Executive Officer, will present at the upcoming Solebury Trout Virtual Investor Conference. The 25 minute presentation includes an interactive Q&A with participants prompted to submit questions electronically. Details are as follows: Date/Time: Tuesday March 31, at 11am EDT Access: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36522/ i ndexl.html Webcast archive: 24 hours following the presentation an archive copy of the presentation will be available on the Company's website at https://www.bergenbio.com/ in section: Investors/Presentations. About BerGenBio BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in -class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com Contacts Richard Godfrey CEO, BerGenBio ASA +47 917 86 304 Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com +47 917 86 513 International Media Relations Mary-Jane Elliot, Chris Welsh, Lucy Featherstone, Carina Jurs Consilium Strategic Communications bergenbio@consilium-comms.com +44 20 3709 5700 Media Relations in Norway Jan Petter Stiff, Crux Advisers stiff@crux.no +47 995 13 891